Townhall.com, Where Your Opinion Counts
Talk Radio:   Bill Bennett   Mike Gallagher   Dennis Prager   Michael Medved   Hugh Hewitt   
BREAKING NEWS  LeftArrow - Townhall.com : Conservative, Political, Republican   RightArrow - Townhall.com : Conservative, Political, Republican  
Columns, funnies & more in your inbox!
Login | What's Hot
  • Check the boxes and send us your email address to receveive your free newsletter
  • Your daily must-read of conservative columns, cartoons and news. Coulter, Sowell, Krauthammer and more.
  • Townhall.com’s weekly inside scoop on what’s happening behind the scenes in the world of politics. When news breaks, we report.
  • Signup to receive the latest daily Townhall cartoons
Wednesday, November 19, 2008
Brian D. Pacampara :: Townhall.com Columnist
4-Star Stocks Poised to Pop: Elan Corp.
by Brian D. Pacampara
Forward Print Share Single Page
Vote on It:
Average Vote:
[+] Text [-]
 
 
Poll
Will the Dems' health care Christmas Present to America be an improvement or detriment to our health care system?


Johnson & Johnson (NYSE: JNJ),

General Electric (NYSE: GE)

CAPS members bearish on ELN also bearish on:

Sangamo BioSciences ,

Ford Motor (NYSE: F), MEMC Electronic Materials (NYSE: WFR)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, some 93% of the 848 members who have rated Elan believe the stock will outperform the S&P 500 going forward. These bulls include postbusters and stockdoc00.

Last week, postbusters urged our community to keep the faith:

I've been following ELN for years and have been burned terribly, but each time the stock rises from the ashes to head for the stars. They have such a great success at innovative new treatments that I have to believe they will be back in the fight for the title again.

A pitch from stockdoc00 in September shares that contrarian spirit, tapping Elan as a misunderstood biotech bargain:

A high risk high reward company with a very promising pipeline, in particular for Alzheimer's and multiple sclerosis. The recent Tysabri scare that precipitated its sudden drop was a huge overreaction by the investor community. While its fundamentals are not up to par compared with other premier pharma co's, it is way oversold and a great buy at its current levels.

What do you think about Elan, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 120,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.
1 2
| Full Article & Comments | < Previous
Share:
Forward Print Single Page
Vote on It:
Average Vote:
 
About The Author

Brian D. Pacampara is an investment expert and analyst for the Motley Fool.

Be the first to read Brian D. Pacampara's column. Sign up today and receive Townhall.com delivered each morning to your inbox.

Join The Debate!

Post Your Comment
(0 comments so Far)
View in ascending order     View in descending order
Sign Up to Post Your CommentsSign Up to Post Your Comments
If you are already registered, click here to login. Otherwise, please take a few seconds to register with Townhall.com. Once you sign up, you’ll be able to post your comments immediately, use the action center, get podcasts, and more!
Note: Fields marked with a red asterisk (*) are required.
Salutation:
First Name:
*
Last Name:
*
Email:
*
Nickname:
*
Note: Nick name will be shown when you post comments.
Address 1:
*
Address 2:
City:
 *
State:
 *
Zip:
 *
Phone:
       
Your daily must-read of conservative columns, cartoons and news. Coulter, Sowell, Krauthammer and more.
(Bi-Weekly) We highlight the best opportunities from our partners for surveys, action items and more.